SCHEDULE: Soleus Capital Discloses 8.6% Stake in NovoCure
Beneficial Ownership Report (Amendment)
Soleus Capital Master Fund and related entities have reported a beneficial ownership of 8.6% in NovoCure Limited, totaling 9,644,872 ordinary shares.
Summary
- Soleus Capital Master Fund, L.P., along with its affiliated entities Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, collectively reported beneficial ownership of 9,644,872 ordinary shares of NovoCure Limited.
- This aggregate amount represents 8.6% of NovoCure Limited's outstanding ordinary shares.
- The percentage is calculated based on 111,981,981 ordinary shares outstanding as of October 24, 2025, as reported in NovoCure's Form 10-Q for the fiscal quarter ended September 30, 2025.
- The reporting persons hold shared voting power and shared dispositive power over all 9,644,872 shares.
- The shares were not acquired or held for the purpose of changing or influencing the control of NovoCure Limited, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 6
Explanation: The filing is a factual disclosure of a significant ownership stake by an institutional investor. While not directly commenting on company performance, a substantial stake (8.6%) by a capital fund can be viewed as a positive signal of confidence in the company's value or future prospects, hence a slightly positive sentiment.
Positives
- A significant institutional stake of 8.6% by Soleus Capital could be interpreted as a vote of confidence in NovoCure Limited's long-term prospects.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment in NovoCure Limited, a company typically operating in the medical device or biotechnology sector, suggesting continued investor interest in the company's market position and potential growth within its industry.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor holding 8.6% of outstanding shares may influence market perception and potentially share price, signaling institutional confidence.
Key Dates
| Date | Description |
|---|---|
| 2025-09-30 | Date of event which requires the filing of this statement. |
| 2025-10-24 | Date as of which 111,981,981 ordinary shares of NovoCure Limited were outstanding, used for percentage calculation. |
| 2025-10-30 | Date NovoCure Limited's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025, was filed with the SEC. |
| 2025-11-07 | Date the Schedule 13G Amendment No. 2 was signed and filed. |
Keywords
NovoCure Limited, Soleus Capital, Beneficial Ownership, Institutional Investor, Equity Stake, G6674U108, Ordinary Shares, SEC Filing, Schedule 13G
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.